|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (3Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
MARLBOROUGH, Mass., Feb. 15, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO) today announced that Gerrit Dispersyn, Dr. Med. Sc., currently President and COO, has been appointed by the Board of Directors as the Company's new CEO, effective March 1.
PHIO Pharmaceuticals Corp. (PHIO) reported third quarter results and filed its Form 10-Q on November 14, 2018. Patent awards, collaborations, pre-clinical advances in the immuno-oncology programs and a financing that opens a runway until 2020 rounded out other key events from June 30 to date. In conjunction with the third quarter release, the company changed its name to PHIO Pharmaceuticals and its ticker symbol to PHIO.
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / Healthcare demand is increasing as an aging population continues to drive new healthcare market growth. The connection between healthcare goods and services is less tied to the economy compared to other sectors, and that could make healthcare stocks the place where investors will look for a hedge as the broader markets see increasing volatility. According to Bureau of Labor Statistics data*, the fastest-growing sectors include healthcare support occupations (23.2% increase from 2016-2026) and healthcare practitioners and technical occupations (15.2%), which entail home health aides, physician assistants and nurse practitioners, among other positions.
- Appoints Gerrit Dispersyn as President and Chief Operating Officer, effective Today - Geert Cauwenbergh to Remain CEO and Member of Board of Directors - Announces Planned Change in Company Name from ...
MARLBOROUGH, Mass. , Nov. 7, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...